Zelira Therapeutics Ltd (ASX: ZLD) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Zelira Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$7.83 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
11.35 million
Earnings per share
-3.236
Dividend per share
N/A
Year To Date Return
-21.11%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Zelira Therapeutics Ltd (ASX: ZLD)
Latest News
⏸️ Investing
3 ASX shares at 52-week highs: Is it too late to invest?
⏸️ Investing
Medicinal cannabis shares are smoking the market
⏸️ Investing
Medicinal cannabis shares were smoked on Monday
⏸️ Investing
Why shares of Medlab Clinical Ltd have risen 37% in 2018
⏸️ Investing
Why the pot stocks crashed lower
⏸️ Investing
How Queensland Bauxite Ltd plans to cash in on cannabis
⏸️ Investing
ALL ORDINARIES finishes higher Friday: 9 shares you missed
⏸️ Investing
Pot stocks rocket on regulation change
⏸️ Investing
Why Aussie pot stocks are smoking the market today
⏸️ Investing
Pot stocks are flying high today
⏸️ Investing
Here are 2017's best performing ASX pot stocks
⏸️ Investing
Why these 4 ASX shares started the week with strong gains
ZLD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Zelira Therapeutics Ltd
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.
ZLD Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 22 Apr 2024 | $0.69 | $-0.02 | -2.82% | 490 | $0.71 | $0.71 | $0.69 |
| 19 Apr 2024 | $0.71 | $-0.01 | -1.39% | 3,894 | $0.72 | $0.72 | $0.71 |
| 18 Apr 2024 | $0.72 | $0.01 | 1.41% | 6,518 | $0.72 | $0.72 | $0.71 |
| 17 Apr 2024 | $0.71 | $-0.01 | -1.39% | 7,495 | $0.72 | $0.72 | $0.71 |
| 16 Apr 2024 | $0.72 | $0.01 | 1.41% | 515 | $0.73 | $0.73 | $0.72 |
| 15 Apr 2024 | $0.71 | $0.02 | 2.90% | 3,516 | $0.69 | $0.75 | $0.69 |
| 12 Apr 2024 | $0.69 | $0.00 | 0.00% | 1,386 | $0.69 | $0.72 | $0.69 |
| 11 Apr 2024 | $0.69 | $-0.01 | -1.43% | 1,968 | $0.70 | $0.71 | $0.69 |
| 10 Apr 2024 | $0.70 | $0.00 | 0.00% | 1,942 | $0.69 | $0.70 | $0.69 |
| 09 Apr 2024 | $0.70 | $0.01 | 1.44% | 3,220 | $0.70 | $0.70 | $0.70 |
| 08 Apr 2024 | $0.70 | $-0.01 | -1.43% | 957 | $0.69 | $0.70 | $0.69 |
| 05 Apr 2024 | $0.70 | $0.00 | 0.00% | 2,359 | $0.70 | $0.70 | $0.70 |
| 04 Apr 2024 | $0.70 | $0.00 | 0.00% | 635 | $0.70 | $0.70 | $0.70 |
| 03 Apr 2024 | $0.70 | $0.01 | 1.46% | 7,408 | $0.69 | $0.70 | $0.69 |
| 02 Apr 2024 | $0.69 | $-0.01 | -1.43% | 3,796 | $0.70 | $0.70 | $0.68 |
| 28 Mar 2024 | $0.70 | $-0.03 | -4.11% | 2,485 | $0.73 | $0.73 | $0.70 |
| 27 Mar 2024 | $0.73 | $0.01 | 1.39% | 609 | $0.72 | $0.73 | $0.72 |
| 26 Mar 2024 | $0.72 | $0.02 | 2.86% | 2,685 | $0.70 | $0.72 | $0.70 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 24 Nov 2023 | Timothy (Tim) Slate | Issued | 100,000 | $47,335 |
Director remuneration.
|
| 24 Nov 2023 | Oludare Odumosu | Issued | 200,000 | $94,669 |
Director remuneration. As per announcement on 24-11-2023
|
| 24 Nov 2023 | Osagie Imasogie | Issued | 150,000 | $71,002 |
Director remuneration.
|
| 24 Nov 2023 | Greg Blake | Issued | 175,000 | $82,836 |
Director remuneration.
|
| 24 Nov 2023 | Donna O'Donnell | Issued | 145,000 | $91,430 |
Director remuneration.
|
| 11 Sep 2023 | Greg Blake | Expiry | 114,290 | $113,147 |
Options expired.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Timothy (Tim) Ryan Slate | Company SecretaryNon-Executive Director | Dec 2016 |
Mr Slate provides accounting and secretarial advice to private and public companies. Mr Slate has over 15 years of experience in chartered accounting.
|
| Dr Oludare Odumosu | Managing Director | Dec 2019 |
Dr Odumosu has over 10 years in corporate pharmaceutical business development, strategy & operational leadership including alliance management, Dr. Odumosu brings a combination of experiences from several academic, public health and life science organizations.
|
| Mr Osagie Imasogie | Non-Executive ChairmanNon-Executive Director | Dec 2019 |
Mr Imasogie has over 30 years of experience in the fields of law, finance, business management, healthcare and the pharmaceutical industry. He is a co-founder and the Senior Managing Partner of PIPV Capital, a Private Equity Firm that is focused on the Life Sciences vertical. Prior to co-founding PIPV Capital, Osagie conceptualized and established GlaxoSmithKline Ventures and was its founding Vice President.
|
| Mr Greg Blake | Executive Director | Feb 2023 |
Mr Blake has led the strategic development and commercialization of several products across a range of therapeutic categories. Throughout his near 20 years working in healthcare Greg has built a foundation of knowledge across marketing and the entire commercial value chain. His work with Rhythm Biosciences as General Manager led the company through the establishment of the pre-launch pathway and commercialization planning for both domestic and international markets.
|
| Dr Donna Gentile O'Donnell | Non-Executive Director | Jun 2023 |
Dr O'Donnell served as Special Assistant to the President, Dr. Stephen K Klasko, and is Senior Vice President for Innovation Partnerships and Programs at Thomas Jefferson University. Donna has led a diverse career in health care, life sciences and public service concentrated in the Greater Philadelphia area. Donna was formerly a principal with O'Donnell Associates, her clients included non-profit organizations, universities, and life science companies, including Cephalon Pharmaceuticals. She was previously the managing director of the Eastern Technology Council for nine years.
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Mr Malik Majeed | 1,134,644 | 10.00% |
| Quincy Street Capital Llc | 456,622 | 4.02% |
| Sharri J Rochlin <Rochlin Family Resource A/C> | 393,168 | 3.46% |
| Mr Zoltan Kerekes | 393,168 | 3.46% |
| Osagie Imasogie | 393,168 | 3.47% |
| Sunset Capital Management Pty Ltd <Sunset Superfund A/C> | 383,725 | 3.38% |
| Ms Lisa Gray | 381,988 | 3.37% |
| Mera I Llc\C | 332,479 | 2.93% |
| Mr Torsten M Geers <The Torsten M Geers Living A/C> | 307,454 | 2.71% |
| Mr Steve Shapiro | 302,571 | 2.67% |
| Mara Gordon | 252,242 | 2.22% |
| Ubs Nominees Pty Ltd | 160,689 | 1.42% |
| Mr Saul Shorr and Mrs Margaret Shorr | 151,285 | 1.33% |
| Dr Chanda Latrice Macias | 146,479 | 1.29% |
| Mera Ii Llc\C | 133,372 | 1.18% |
| Citicorp Nominees Pty Limited | 132,506 | 1.17% |
| Oludare Odumosu | 131,766 | 1.16% |
| Muller Ct Pty Ltd <Muller Super Fund A/C> | 118,107 | 1.04% |
| Mr Daniel Hexter and Mrs Shannon Hexter | 103,389 | 0.91% |
| Geers Egag Llc | 85,715 | 0.76% |
